Literature DB >> 32150306

Endogenous ethanol produced by intestinal bacteria induces mitochondrial dysfunction in non-alcoholic fatty liver disease.

Xiao Chen1, Zheng Zhang2, Huan Li3, Jiangtao Zhao3, Xiao Wei3, Weishi Lin3, Xiangna Zhao3, Aimin Jiang1, Jing Yuan4.   

Abstract

BACKGROUND AND AIM: A causal relationship between changes of the gut microbiome and non-alcoholic fatty liver disease (NAFLD) remains unclear. We demonstrated that endogenous ethanol (EnEth) produced by intestinal microbiota is likely a causative agent of NAFLD.
METHODS: Two mutants with different alcohol-producing abilities, namely, W14-adh and W14Δadh, were constructed using the clinical high alcohol-producing (HiAlc) Klebsiella pneumoniae strain W14 as a parent. Damage to hepatocytes caused by bacteria with different alcohol-producing capacities was evaluated (EtOH group as positive control). The ultrastructural changes of mitochondria were assessed via transmission electron microscopy (TEM). Hepatic levels of mitochondrial reactive oxygen species (ROS), DNA damage, and adenosine triphosphate were examined.
RESULTS: The results illustrated that steatosis was most severe in the W14-adh group, followed by the W14 group, whereas the W14Δadh group had few fatty droplets. TEM and examination of related protein expression revealed that the mitochondrial integrity of HepG2 hepatocytes was considerably damaged in the EtOH and bacteria treatment groups. The impaired mitochondrial function in HepG2 hepatocytes was evidenced by reduced adenosine triphosphate content and increased mitochondrial ROS accumulation and DNA damage in the EtOH and bacteria treatment groups, especially the W14-adh group. Meanwhile, liver injury and mitochondrial damage were observed in the hepatocytes of mice. The livers of mice in the W14-adh group, which had the highest ethanol production, exhibited the most serious damage, similar to that in the EtOH group.
CONCLUSIONS: EnEth produced by HiAlc bacteria induces mitochondrial dysfunction in NAFLD.
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Klebsiella pneumoniae; NAFLD; endogenous ethanol; mitochondrial dysfunction

Mesh:

Substances:

Year:  2020        PMID: 32150306     DOI: 10.1111/jgh.15027

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  15 in total

Review 1.  Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis.

Authors:  Nan Yao; Yixue Yang; Xiaotong Li; Yuxiang Wang; Ruirui Guo; Xuhan Wang; Jing Li; Zechun Xie; Bo Li; Weiwei Cui
Journal:  Front Nutr       Date:  2022-06-17

Review 2.  Infections at the nexus of metabolic-associated fatty liver disease.

Authors:  Robim M Rodrigues; Tamara Vanhaecke; Joost Boeckmans; Matthias Rombaut; Thomas Demuyser; Baptist Declerck; Denis Piérard; Vera Rogiers; Joery De Kock; Luc Waumans; Koen Magerman; Reinoud Cartuyvels; Jean-Luc Rummens
Journal:  Arch Toxicol       Date:  2021-05-24       Impact factor: 5.153

3.  Gut fermentation syndrome: A systematic review of case reports.

Authors:  Ahmed B Bayoumy; Chris J J Mulder; Jaap J Mol; Maarten E Tushuizen
Journal:  United European Gastroenterol J       Date:  2021-04-22       Impact factor: 4.623

4.  Neuroprotective effect of Ginsenoside Re against neurotoxin‑induced Parkinson's disease models via induction of Nrf2.

Authors:  Juhui Qiao; Yuchu Zhao; Ying Liu; Siyu Zhang; Wenxue Zhao; Shichao Liu; Meichen Liu
Journal:  Mol Med Rep       Date:  2022-05-11       Impact factor: 3.423

Review 5.  Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications.

Authors:  Jiezhong Chen; Luis Vitetta
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

Review 6.  Intestinal Microbiota and Liver Diseases: Insights into Therapeutic Use of Traditional Chinese Medicine.

Authors:  Tingshuai Wang; Shaodong Huang; Cong Wu; Na Wang; Rongzhen Zhang; Minggang Wang; Dewen Mao
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-22       Impact factor: 2.629

Review 7.  Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease.

Authors:  Eunju Park; Jin-Ju Jeong; Sung-Min Won; Satya Priya Sharma; Yoseph Asmelash Gebru; Raja Ganesan; Haripriya Gupta; Ki Tae Suk; Dong Joon Kim
Journal:  Cells       Date:  2021-10-02       Impact factor: 6.600

8.  Antibiotic Disruption of the Gut Microbiota Enhances the Murine Hepatic Dysfunction Associated With a High-Salt Diet.

Authors:  Zheng Zhang; Mengjie Li; Bo Cui; Xiao Chen
Journal:  Front Pharmacol       Date:  2022-02-11       Impact factor: 5.810

Review 9.  Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?

Authors:  Agostino Di Ciaula; Salvatore Passarella; Harshitha Shanmugam; Marica Noviello; Leonilde Bonfrate; David Q-H Wang; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

Review 10.  Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Ignazio Grattagliano; Agostino Di Ciaula; Jacek Baj; Emilio Molina-Molina; Harshitha Shanmugam; Gabriella Garruti; David Q-H Wang; Piero Portincasa
Journal:  Methods Mol Biol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.